Bio-Techne (TECH)
NASDAQHealth CareBiotechnologySnapshot 2026-07-07
$70.61-0.44%
Close 2026-07-07 · 1-day change
Reading TECH? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track TECH free→NASDAQHealth CareBiotechnologySnapshot 2026-07-07
Reading TECH? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track TECH free→Warn: Management is running behind on a stated commitment.
Bio-Techne improves profit margins from 12.2% to 24.2% in one year. It keeps paying a steady dividend of $0.08 per share. The acquisition by Merck KGaA boosts growth and market position. Revenue is stable near $311 million despite market challenges.
Revenue declined 2% year over year, showing weak growth. Leadership changes in Diagnostics may hurt execution. The stock trades at a high price-to-earnings ratio of 37.6, risking valuation pressure.
The market expects about 4.5% revenue growth and prices the stock roughly 32% above our estimate of intrinsic value. Our estimate is below the Street median by 17%, reflecting a more cautious outlook on growth and profitability.
Breaks if: Dividend per share falls below $0.08
Continue paying a quarterly cash dividend of $0.08 per share to shareholders.
Stated as a priority in 4 of last 4 quarters. The company consistently paid a quarterly dividend of $0.08 per share from 2025-Q3 through 2026-Q3. This steady dividend payment matches management's commitment to maintain shareholder returns.
Standing thesis, reviewed periodically — not a price target or advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Dividend per share was $0.08 for the quarter.”
“Dividend per share was $0.08 for the quarter.”
“Dividend per share was $0.08 for the quarter.”
“Dividend per share was $0.08 for the quarter.”
Breaks if: Operating margin falls below 15% in 2026-Q3
Continue ongoing productivity and cost containment initiatives to improve operating margins and profitability.
Stated as a priority in 6 of last 6 quarters. GAAP operating margin improved significantly from 12.2% in 2025-Q3 to 24.2% in 2026-Q3, reflecting favorable impacts from profitability initiatives and divestitures. Adjusted operating margin remained stable around 34%, indicating ongoing focus on cost control and productivity. Management's statements align with the financial improvements, showing delivery on profitability focus.
“Operating margin favorably impacted by ongoing profitability initiatives and divestiture.”
“Adjusted operating margin increased due to productivity initiatives and foreign exchange.”
“Adjusted operating margin favorably impacted by productivity initiatives and divestiture.”
“Profitability initiatives contributed to adjusted operating margin of 32.0%.”
“Profitability initiatives and volume leverage drove adjusted operating margin of 34.9%.”
“Adjusted operating margin impacted by volume leverage offset by incentive compensation accruals.”
Breaks if: Revenue falls below $295 million in 2026-Q3
Focus on driving organic revenue growth across segments despite market challenges and divestitures.
Stated as a priority in 6 of last 6 quarters. Revenue declined slightly from $316.2M in 2025-Q3 to $311.4M in 2026-Q3 (-2%), with Protein Sciences segment down 1% and Diagnostics and Spatial Biology down 4%. Management consistently emphasized growth in large pharma and stabilization in academic markets, but overall revenue trajectory shows limited progress against growth targets.
“Large pharma again led results with sixth consecutive quarter of double-digit growth, offset by lag in emerging biotech.”
“Early signs of improvement in biopharma end-market, encouraging momentum in cell and gene therapy and protein analysis.”
“Observed encouraging signs of stabilization in US academic end market and continued strength from large pharma customers.”
“Strong performance in proteomic analytic and cell therapy growth pillars drove 4% organic growth in Protein Sciences segment.”
“Pharma end market continued to improve, especially from large pharma partners, leading to solid performance.”
“Improving biopharma end-market conditions combined with momentum of cell and gene therapy workflow solutions.”
Complete divestiture of Exosome Diagnostics business to focus on high-growth non-CLIA product lines.
Stated as a priority in 4 of last 4 quarters. The Exosome Diagnostics business was divested with held-for-sale status as of June 30, 2025. This divestiture contributed to improved operating margins in the Diagnostics and Spatial Biology segment, which rose from 9.4% in 2025-Q3 to 12.1% in 2026-Q3. Management consistently highlighted this strategic divestiture as a key step to strengthen profitability and focus on growth pillars, showing delivery on this priority.
Breaks if: Material integration problems or loss of key customers reported
“Exosome Diagnostics divestiture favorably impacted operating margin.”
“Completed divestiture of Exosome Diagnostics business including ExoDx Prostate test.”
“Announced divestiture of Exosome Diagnostics business to increase focus on high-growth areas.”
“Exosome Diagnostics divestiture contributed to adjusted operating margin improvements.”